Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules
- 1.1k Downloads
This study aimed to determine whether progress in developing bleeding risk estimation tools for patients on oral anticoagulant therapy has been made since 2006 when we last systematically reviewed this topic, and to refresh previously published quantitative evaluations of the clinical prediction rules (CPRs) available for estimating bleeding risk in patients on oral anticoagulant therapy. A systematic review of English language literature published since December 2006 was conducted when our previous systematic review ended. Studies were analyzed for predictive performance using likelihood ratios. Six studies detailed CPRs used to assess risk of bleeding prior to commencing warfarin therapy, four of which were included in the analysis. Three studies evaluated new CPRs (“RIETE” and “HAS-BLED”). One of the studies was a further validation of the modified outpatient bleeding risk index (mOBRI) in patients with atrial fibrillation. Individual trial and pooled analyses using likelihood ratios for mOBRI and HAS-BLED showed they have weak predictive accuracy. A RIETE score of 0 point was moderately predictive of the absence of major bleeding. None of the CPRs exhibited sufficient predictive accuracy or had sufficient validation to be recommended for routine use in practice. None of the available CPRs exhibit sufficient predictive accuracy or have trials evaluating the impact of their use on patient outcomes. Hence, no existing oral anticoagulation major bleeding CPR can be recommended for routine use in practice at present.
KeywordsBleeding Warfarin Anticoagulants Clinical prediction rules
Conflicts of interest
No funding was provided to assist in the preparation of the manuscript. The authors have no potential conflicts of interest to declare.
- 2.Connolly SJ, Ezekowitz MD, Yusuk S, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY). N Engl J Med 361. 10.1056/NEJMoa0905561
- 3.Schulman S, Kearon C, Kakkar AK, et al. (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER). N Engl J Med 361. 10.1056/NEJMoa0906598
- 8.ROCKET AF Study Investigators (2010) Rivaroxaban-once daily, oral, direct factor XA inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation rationale and design of the ROCKET AF study. Am Heart J 159(3):340–347.e.1Google Scholar
- 12.The Cochrane Library. Cochrane reviewers’ handbook 5.0.2. 2009; available at http://www.cochrane-handbook.org. Accessed 12 December 2010
- 13.Liberati A, Altman DG, Tetzlaff D et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W-65–W-94Google Scholar
- 23.Sackett DL, Haynes RB, Guyatt GH, Tugwell P (1991) Clinical epidemiology—a basic science for clinical medicine. London, Little Brown 51–68Google Scholar
- 29.Lip GYH, Frison L, Halperin JL, Lane DA (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol 57:173–180PubMedCrossRefGoogle Scholar
- 31.Ruiz-Giminez N et al (2008) Predictive variables for major bleeding events in patients presenting with document acute venous thromboembolism: findings from the RIETE registry. Thromb Haemost 100:26–31Google Scholar
- 40.Canadian Cardiovascular Society (2010) Canadian Cardiovascular Society 2010 Atrial Fibrillation Guidelines. Available at http://www.ccsguidelineprograms.ca/index.php?option=com_content&view=article&id=111&Itemid=66. Accessed 12 December 2010